Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 3.6% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences Corporation (NYSE: EW) is a medical technology company specializing in heart valves and hemodynamic monitoring. The company is known for its innovative products in the cardiovascular space.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 3.6% on Nov 18, 2024 17:17

• Despite facing multiple securities class action lawsuits and allegations of securities law violations, Edwards Lifesciences (EW) saw a strong bullish movement in the market today.
• Investors might be optimistic about the company's ability to navigate through the legal challenges and maintain its market position.
• The bullish trend could also be attributed to positive developments in the company's core business operations or potential market opportunities that investors are anticipating.
• It appears that market sentiment towards Edwards Lifesciences (EW) remains resilient in the face of legal uncertainties, driving the stock price higher.

EW Price Chart

EW Technical Analysis

EW News

EW LEGAL DEADLINE: The Edwards Lifesciences Securities Class Action Deadline is Approaching - Contact BFA Law Now if You Lost Money ( NYSE:EW ) - Edwards Lifesciences ( NYSE:EW )

NEW YORK, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation EW and certain of the Company's senior executives for potential violations of the federal securities laws.

https://www.benzinga.com/pressreleases/24/11/g42033896/ew-legal-deadline-the-edwards-lifesciences-securities-class-action-deadline-is-approaching-contact

EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - Edwards Lifesciences ( NYSE:EW )

SAN DIEGO, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation EW securities between February 6, 2024 and July 24, 2024, inclusive ( the "Class Period" ) , have until Friday, December 13, 2024 to seek ...

https://www.benzinga.com/pressreleases/24/11/g42030563/ew-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-edwards-lifesciences-corporation-i

EW FRAUD ALERT: Suffer Losses on Your Edwards Lifesciences Securities? Contact BFA Law before December 13 Securities Fraud Class Action Deadline ( NYSE:EW ) - Edwards Lifesciences ( NYSE:EW )

NEW YORK, Nov. 16, 2024 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation EW and certain of the Company's senior executives for potential violations of the federal securities laws.

https://www.benzinga.com/pressreleases/24/11/g42023261/ew-fraud-alert-suffer-losses-on-your-edwards-lifesciences-securities-contact-bfa-law-before-decemb

Edwards Lifesciences ( EW ) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization - Hagens Berman - Edwards Lifesciences ( NYSE:EW )

SAN FRANCISCO, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Edwards Lifesciences Corporation EW investors who suffered substantial losses to submit your losses now.

https://www.benzinga.com/pressreleases/24/11/g42014017/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capitalizati

Edwards Lifesciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before December 13, 2024 to Discuss Your Rights - EW - Edwards Lifesciences ( NYSE:EW )

NEW YORK, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation EW. Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

https://www.benzinga.com/pressreleases/24/11/g41913294/edwards-lifesciences-corporation-sued-for-securities-law-violations-contact-the-gross-law-firm-bef

Trending Today

Sui ($SUI) Crypto Forecast: Down 5.6% Today

Bitcoin SV ($BSV) Crypto Forecast: Up 8.0% Today

Aptos ($APT) Crypto Forecast: Down 9.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.3% Today

Floki ($FLOKI) Crypto Forecast: Up 5.1% Today

Litecoin ($LTC) Crypto Forecast: Up 5.9% Today

Polkadot ($DOT) Crypto Forecast: Down 7.1% Today

Avalanche ($AVAX) Crypto Forecast: Down 5.1% Today

Bitcoin Cash ($BCH) Crypto Forecast: Up 16.6% Today

The Graph ($GRT) Crypto Forecast: Down 7.3% Today

Edwards Lifesciences Corporation Price History

18.10.2024 - EW Stock was up 3.6%

• Despite facing multiple securities class action lawsuits and allegations of securities law violations, Edwards Lifesciences (EW) saw a strong bullish movement in the market today.
• Investors might be optimistic about the company's ability to navigate through the legal challenges and maintain its market position.
• The bullish trend could also be attributed to positive developments in the company's core business operations or potential market opportunities that investors are anticipating.
• It appears that market sentiment towards Edwards Lifesciences (EW) remains resilient in the face of legal uncertainties, driving the stock price higher.

30.09.2024 - EW Stock was down 4.7%

• Lawsuits and alerts about losses appear to have impacted investor confidence in Edwards Lifesciences Corporation (EW).
• Trading trends show a significant focus on put options, suggesting a bearish sentiment among investors.
• An upcoming deadline for investors who purchased shares during a specific period may have contributed to the selling pressure on EW stock.
• Overall, negative news flow and legal actions surrounding EW likely influenced the bearish market movement observed today.

08.09.2024 - EW Stock was up 6.1%

• The bullish movement in EW could be attributed to investors recognizing the company as a better value option compared to its competitor TFX.
• Positive sentiment surrounding Edwards Lifesciences' products and potential growth prospects might have contributed to the stock's upward trajectory.
• The comparison with TFX could have sparked increased interest in EW, leading to higher demand and a bullish market movement.

28.09.2024 - EW Stock was down 2.5%

• The stock of Edwards Lifesciences Corporation (EW) experienced a strong bearish movement today.
• The market reacted negatively to the series of investor alerts and class action lawsuit announcements against Edwards Lifesciences Corporation.
• The legal actions and fraud alerts likely raised concerns among investors, leading to a sell-off of EW shares.
• The uncertainty surrounding the lawsuits and potential violations of securities laws may have contributed to the bearish sentiment and downward pressure on the stock price.

17.08.2024 - EW Stock was down 2.5%

• Despite bullish options activity, Edwards Lifesciences (EW) experienced a strong bearish movement today.
• The discrepancy between the bullish options activity and the bearish market movement could indicate a divergence in sentiment among investors.
• It's possible that external factors such as broader market trends or specific company news overshadowed the optimistic options activity, leading to the bearish movement in EW's stock.
• Investors should closely monitor any upcoming developments or news that could provide more clarity on the stock's unexpected performance.

05.08.2024 - EW Stock was down 6.1%

• There is a notable options frenzy surrounding Edwards Lifesciences, suggesting that well-funded investors are taking a bearish view on the stock.
• This negativity could be attributed to concerns related to the company's financial performance, potential regulatory challenges, or broader market conditions affecting the healthcare industry.
• Investors are advised to closely monitor these indicators as they could signify a shift in sentiment towards Edwards Lifesciences, potentially resulting in further downward pressure on the stock price.

07.02.2024 - EW Stock was up 5.2%

• The stock of Edwards Lifesciences (EW) experienced a strong bullish movement today.
• The positive market movement can be attributed to the company's recent earnings report, which showed a 2% increase since the last report, indicating strong performance and potential growth.
• Additionally, Edwards Lifesciences (EW) is benefiting from the global adoption of its RESILIA platform and the growth in Transcatheter Aortic Valve Replacement (TAVR) procedures, signaling promising prospects for the company's future revenue and market position.
• The company's strategic focus on expanding its portfolio in critical care, TAVR, and other innovative technologies reflects a proactive approach to driving growth and staying competitive in the healthcare industry, further boosting investor confidence in Edwards Lifesciences (EW).

15.04.2024 - EW Stock was up 5.0%

• The bullish movement in EW stock could be attributed to the European launch of the SAPIEN 3 Ultra RESILIA valve, showcasing the company's commitment to technological advancements in the cardiovascular field.
• The news of an executive selling shares worth over $73k might have initially raised concerns, but the positive market sentiment towards the new product launch overshadowed this development.
• Investors seem optimistic about the value of Edwards Lifesciences (EW) following the introduction of the new valve, potentially driving the stock price higher as the market perceives it as a significant advancement in the company's product portfolio.

26.06.2024 - EW Stock was down 8.6%

• Edwards Lifesciences shares plunged 31% after being downgraded by J.P. Morgan and Truist due to concerns about heart valve replacement sales growth.
• The stock hit a 52-week low, trading at $60.53, reflecting the negative sentiment surrounding the company.
• Dampened expectations for heart valve replacement sales growth contributed to the stock's sharp decline.
• The overall market sentiment, particularly in the tech sector, remained in the "Fear" zone, with tech stocks faltering and impacting investor confidence in companies like Edwards Lifesciences.

25.06.2024 - EW Stock was down 29.7%

• We observed that Edwards Lifesciences faced challenges in sales performance for the second quarter, coupled with a conservative outlook for the third quarter, prompting a decline in the stock value.
• Analysts revised their projections for EW downwards due to unmet expectations in TAVR (Transcatheter Aortic Valve Replacement) growth, leading to a reduction in the price target.
• The recent acquisitions of JenaValve and Endotronix by Edwards Lifesciences may have influenced investor confidence, contributing to the stock price decrease.
• Following the release of the earnings report showing missed growth targets, negative sentiment towards the company likely drove the considerable decrease in Edwards Lifesciences stock value.

25.06.2024 - EW Stock was down 23.2%

• Edwards Lifesciences (EW) stock experienced a significant 22% decline today.
• The company's earnings report for the second quarter of 2024 revealed mixed results, with adjusted EPS slightly beating estimates but revenue falling short of expectations.
• Investors were particularly disappointed with the lower-than-expected growth in the Transcatheter Aortic Valve Replacement (TAVR) segment, which impacted the overall revenue performance.
• Additionally, market trends and concerns about divestiture challenges might have added to the negative sentiment surrounding Edwards Lifesciences stock, contributing to the bearish movement observed today.

25.06.2024 - EW Stock was down 28.3%

• Edwards Lifesciences (EW) stock witnessed a sharp 22% drop following disappointing revenue figures in the second-quarter earnings.
• While the company exceeded earnings per share estimates, its revenue of $1.63 billion fell short of the $1.65 billion expected by analysts.
• The slower growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) product group and underperformance in Transcatheter Aortic Valve Replacement (TAVR) were contributing factors to the negative reaction from the market.
• Investors responded unfavorably to the revenue miss, overshadowing the positive earnings beat and robust performance of the TMTT product group.